Second international congress on immunopharmacology: delivery systems and current strategies for drug design

Reinaldo Acevedo, Mario Landys, Armando Acosta, Herve Bercovier, Mohd Nor Norazmi, Valerie Ferro, Maria Elena Sarmiento

Research output: Contribution to journalSpecial issuepeer-review

50 Downloads (Pure)

Abstract

The 2nd International Congress on Immunopharmacology was held in June of 2011 at the Conference Center of Plaza America in Varadero, Cuba. The main goal of this meeting was to provide state-of-the-art communications for scientists, manufacturers, regulators and healthcare workers, to accelerate progress in the development of biological and biotechnological products and to promote exchange/scientific cooperation between researchers. 300 delegates from 22 countries attended the conference. The wide-ranging programme commenced with a plenary session and then split into a series of parallel workshops and symposia, covering “Advances in Immunopharmacology”, “Neuroimmunology”, “Therapeutic Biological Products”, “Prophylaxis and Treatment of Helicobacter pylori”, “Pharmacology of Cytochrome P450”, “Hereditary Ataxias” and “Delivery Systems and Current Strategies for Drug Design”. In this last Symposium, a substantial body of data was presented relating to the development of delivery systems with adjuvant and vaccine potential and also to strategies focused in therapeutic and prophylactic approaches against tuberculosis. This issue is dedicated to some of the results presented in this area.
Original languageEnglish
Article numberS1
Number of pages2
JournalBMC Immunology
Volume14
Issue numberSupplement 1
DOIs
Publication statusPublished - 25 Feb 2013
EventSecond International Congress on Immunopharmacology 2011 - Conference Center of Plaza America, Varadero, Cuba
Duration: 26 Jun 201130 Jun 2011

Keywords

  • immunopharmacology
  • drug design
  • strategies

Fingerprint

Dive into the research topics of 'Second international congress on immunopharmacology: delivery systems and current strategies for drug design'. Together they form a unique fingerprint.

Cite this